轉基因生物（GMO）小組此前就轉基因大豆A2704-12預期用途對人類和動物健康及環(huán)境影響做了風險評估，發(fā)現(xiàn)這種大豆與傳統(tǒng)大豆和商業(yè)大豆品種一樣安全和有營養(yǎng)。經(jīng)過評估，新的測序數(shù)據(jù)和對新序列進行的生物信息學分析沒有引起安全問題。因此，EFSA得出結論，大豆BPS - CV127 - 9的原始風險評估仍然有效。
部分原文報道如下：
The GMO Panel has previously assessed genetically modified （GM） soybean A2704‐12. This soybean was found to be as safe and nutritious as its conventional counterpart with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 5 June 2018, the European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soybean A2704‐12 and to indicate whether the previous conclusions of the GMO Panel on the risk assessment of GM soybean A2704‐12 remain valid. The new sequencing data indicated seven nucleotide differences as compared to the sequence originally provided in application EFSA‐GMO‐NL‐2005‐18; six nucleotides in the 3′ genomic flanking region and one nucleotide in the soybean chloroplast DNA fragment located 5′ to the insert. Another nucleotide located in a polylinker region of the insert reported as ambiguous in the originally submitted sequence was resolved in the new sequence data. based on the information provided on the locations affected by the reported nucleotide differences, no open reading frames （ORFs） spanning the junction site between the insert and the 3′ genomic flanking DNA are affected by the differences in the 3′ genomic flanking region and were therefore excluded from the assessment.
本文由食品伙伴網(wǎng)食品資訊中心編輯，供網(wǎng)友參考，歡迎轉載，轉載請注明出處！有任何疑問，請聯(lián)系news@foodmate.net。
